Cargando…

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation (n = 39), patients with P53WT refractory solid tumors enrolled to rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gluck, W. Larry, Gounder, Mrinal M., Frank, Richard, Eskens, Ferry, Blay, Jean Yves, Cassier, Philippe A., Soria, Jean-Charles, Chawla, Sant, de Weger, Vincent, Wagner, Andrew J., Siegel, David, De Vos, Filip, Rasmussen, Erik, Henary, Haby A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Phase I Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211202/ https://www.ncbi.nlm.nih.gov/pubmed/31359240 http://dx.doi.org/10.1007/s10637-019-00840-1

Ejemplares similares

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
por: Moschos, Stergios J., et al.
Publicado: (2022)

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
por: Italiano, Antoine, et al.
Publicado: (2021)

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
por: Chiu, Joanne W., et al.
Publicado: (2015)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
por: Her, Nam-Gu, et al.
Publicado: (2018)

Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
por: Uy, Geoffrey L., et al.
Publicado: (2020)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
por: Marshall, John, et al.
Publicado: (2012)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
por: Even, C., et al.
Publicado: (2019)

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
por: Leary, Alexandra, et al.
Publicado: (2018)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

A phase Ib study of everolimus combined with metformin for patients with advanced cancer
por: Molenaar, Remco J., et al.
Publicado: (2017)

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
por: Olmedo, María Eugenia, et al.
Publicado: (2021)

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
por: Cirkel, Geert A., et al.
Publicado: (2016)

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
por: LoRusso, Patricia, et al.
Publicado: (2022)

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
por: van der Biessen, Diane A. J., et al.
Publicado: (2018)

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
por: Beumer, J. H., et al.
Publicado: (2007)

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer
por: Okamoto, Isamu, et al.
Publicado: (2009)

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
por: Soto, Elena, et al.
Publicado: (2010)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2011)

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
por: Wang-Gillam, Andrea, et al.
Publicado: (2011)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
por: Gordon, Michael S., et al.
Publicado: (2012)

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer
por: Kordes, Sil, et al.
Publicado: (2012)

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
por: Yau, Thomas, et al.
Publicado: (2012)

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
por: Annunziata, Christina M., et al.
Publicado: (2012)

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
por: Awada, A. H., et al.
Publicado: (2012)

Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
por: Nwankwo, Nwabundo, et al.
Publicado: (2012)

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
por: Blais, Normand, et al.
Publicado: (2013)

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer
por: Boku, Narikazu, et al.
Publicado: (2013)

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses
por: Uhl, Wolfgang, et al.
Publicado: (2013)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t2jf34338ktiemhqalre0tbeau